Please assess the completion status of the following clinical trial:

Trial Title: Study of the Oral Factor D (FD) Inhibitor ALXN2050 in PNH Patients as Monotherapy

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~1. Diagnosis of PNH.~2. Male or female, ≥ 18 years of age~Eligibility Criteria:~Eligibility Criteria Specific for Group 1:~1. PNH Patients who have no history of treatment with any complement inhibitor at any dose.~2. PNH Type III erythrocyte or granulocyte clone size ≥10%~3. Absolute reticulocyte count ≥100×10\^9/liter \[L\].~4. Anemia (Hgb \<10.5 grams/deciliter \[g/dL\]).~5. LDH ≥1.5× upper limit of normal.~6. Platelet count ≥30,000/microliter (µL)~7. Absolute neutrophil count (ANC) ≥750/ µL.~Eligibility Criteria Specific for Group 2:~1. Stable background regimen of at least 24 weeks for eculizumab without change in dose or interval for at least the past 8 weeks~2. Anemia (Hgb \<10 g/dL)~3. Absolute reticulocyte count ≥100×10\^9/L~4. Platelet count ≥30,000/µL~5. Absolute neurophil count (ANC) ≥750/ µL~Eligibility Criteria Specific for Group 3:~1. Patient received danicopan during Study ACH471-103~Key Exclusion Criteria:~1. History of a major organ transplant or hematopoietic stem cell/marrow transplant .~2. Known aplastic anemia or other bone marrow failure that requires HSCT, or if these patients are on immunosuppressive agents for less than 24 weeks.~3. Known underlying bleeding disorders or any other conditions leading to anemia not primarily associated with PNH.~4. Estimated glomerular filtration rate \<30 milliliters/minute/1.73 meters squared and/or are on dialysis.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Open-label ALXN2050 Monotherapy (Type: EXPERIMENTAL): Experimental: Open-label ALXN2050 Monotherapy ALXN2050 orally administered~Group 1: Patients with PNH who are treatment naïve~Group 2: Patient with PNH who have received complement component 5 (C5) inhibition with eculizumab for at least 6 months, who continue to experience anemia and reticulocytes above the upper limit of normal (ULN)~Group 3: Patients with PNH who have received danicopan monotherapy during study ACH471-103

Based on this trial design, predict the completion outcome and termination type (if applicable).